Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

What Did the AASM Conclude About Cannabis for OSA? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The AASM on cannabis for OSA provides a critical overview of current evidence regarding cannabinoid use in obstructive sleep apnoea. The American Academy of Sleep Medicine evaluates clinical research to offer guidance on safe and effective treatment options. 

Am I eligible for medical cannabis for pain relief?

Key Findings from AASM 

The AASM on cannabis for OSA highlights that current studies, including dronabinol and THC interventions, are limited in scale and duration, making it difficult to recommend cannabinoids as standard therapy. 

Evidence Assessment 

The American Academy Sleep Medicine’s position stresses that while some trials show modest reductions in apnoea-hypopnea index, there is insufficient evidence for long-term safety or consistent efficacy. 

Clinical Guidance 

The AASM guidance on cannabis advises clinicians to prioritise established treatments, such as CPAP, and consider cannabinoids only within research or carefully monitored contexts. 

Safety Considerations 

Potential side effects, including sedation, cognitive impairment, or cardiovascular effects, are emphasised, reinforcing the need for careful patient selection and dose management. 

The AASM on cannabis for OSA concludes that cannabinoids remain experimental in sleep apnoea management. The American Academy Sleep Medicine’s position and AASM guidance on cannabis underline the importance of further large-scale trials before routine clinical use can be recommended. 

If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories